Company / R&D Expense
Marker Therapeutics, Inc. R&D Expense History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$27.8M
FY2021
5-year range
$5.3M / $27.8M
FY2018-FY2021
Trend
+117.7%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $28M over the past 3 years.
Based on SEC 10-K filings.
$28M in FY2021.
Improved from $5M to $28M over the past 3 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +74.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +74.3%, indicating consistent growth.
- In FY2021, r&d expense increased 117.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $27.8M | +117.7% |
| FY2019 | $12.8M | +143.1% |
| FY2018 | $5.3M | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026